No photo of Babafemi O Taiwo

View Scopus Profile

Babafemi O Taiwo

  • 1728 Citations
20002023
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Certifications and Licenses

Internal Medicine
Infectious Disease

Training Experience

1996Residency, Berkshire Medical Center
2006Fellowship, Northwestern University, McGaw Medical Center (Northwestern Memorial Hospital)

Education/Academic qualification

MBBS, University of Ibadan, Nigeria

… → 1991

Research interests

  • Fever of Unknown Origin
  • Fungal Infections
  • Human Immunodeficiency Virus (HIV/AIDS)
  • Influenza
  • Lyme Disease
  • Malaria
  • Musculoskeletal Infections
  • Osteomyelitis
  • Prosthetic Joint Infections
  • Sexually Transmitted Diseases
  • Skin Infections (MRSA)
  • Soft

Fingerprint Dive into the research topics where Babafemi O Taiwo is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 13 Similar Profiles
HIV Medicine & Life Sciences
HIV-1 Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Tenofovir Medicine & Life Sciences
HIV Infections Medicine & Life Sciences
Nigeria Medicine & Life Sciences
Viral Load Medicine & Life Sciences
Lamivudine Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2004 2023

Protocol Funds, Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG) [UM1AI068636]

Taiwo, B. O.

University of California, Los Angeles, National Institute of Allergy and Infectious Diseases

12/1/18 → 11/30/19

Project: Research project

Financial Management
Acquired Immunodeficiency Syndrome
Clinical Trials
Budgets
Clinical Protocols

ACTG A5322 Protocol Vice Chair Support

Taiwo, B. O.

University of California, Los Angeles, National Institute of Allergy and Infectious Diseases

12/1/18 → 11/30/19

Project: Research project

Publications

ACTG Taiwo AEC Committee Support

Taiwo, B. O.

University of California, Los Angeles, National Institute of Allergy and Infectious Diseases

12/1/18 → 11/30/19

Project: Research project

Committee Membership
Publications

Clinical Core - The Center for Innovation in Point-of-Care Technologies for HIV/AIDS at Northwestern University (C-THAN)

Achenbach, C. J., D'Aquila, R. T., Hawkins, C. A., Hirschhorn, L. R., Maiga, M., Murphy, R. L., Taiwo, B. O. & Hou, L.

National Institute of Biomedical Imaging and Bioengineering

9/11/18 → 5/31/23

Project: Research project

Point-of-Care Systems
Acquired Immunodeficiency Syndrome
HIV
Biomedical Engineering
Mali

Intensive Combination Approach to Rollback the Epidemic (iCARE) in Nigerian Adolescents

Hirschhorn, L. R., Janulis, P. F. & Taiwo, B. O.

National Institute of Child Health and Human Development

9/6/18 → 8/31/20

Project: Research project

HIV
Nigeria
Research
Capacity Building
Telemedicine

Research Output 2000 2019

Comparable viral decay with initial dolutegravir plus lamivudine versus dolutegravir-based triple therapy

Gillman, J., Janulis, P. F., Gulick, R., Wallis, C. L., Berzins, B., Bedimo, R., Smith, K., Aboud, M. & Taiwo, B. O., Aug 1 2019, In : The Journal of antimicrobial chemotherapy. 74, 8, p. 2365-2369 5 p.

Research output: Contribution to journal › Article

Lamivudine
Viral Load
Therapeutics
Nonparametric Statistics
dolutegravir

Differences in statin utilization and lipid lowering by race, ethnicity, and HIV status in a real-world cohort of persons with human immunodeficiency virus and uninfected persons

Riestenberg, R. A., Furman, A., Cowen, A., Pawlowksi, A., Schneider, D., Lewis, A. A., Kelly, S., Taiwo, B. O., Achenbach, C. J., Palella Jr, F. J., Stone, N. J., Lloyd-Jones, D. M. & Feinstein, M. J., Mar 1 2019, In : American heart journal. 209, p. 79-87 9 p.

Research output: Contribution to journal › Article

Hydroxymethylglutaryl-CoA Reductase Inhibitors
HIV
Lipids
HIV Infections
Cardiovascular Diseases
1 Citation (Scopus)

Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: Week 48 outcomes from ACTG 5353

Nyaku, A. N., Zheng, L., Gulick, R. M., Olefsky, M., Berzins, B., Wallis, C. L., Godfrey, C., Sax, P. E., Acosta, E. P., Haas, D. W., Smith, K. Y., Sha, B. E., Van Dam, C. N., Taiwo, B. O., Hawkins, E., Kumwenda, J., Hernandez, A., Ha, B., Jarocki, B., Tegha, G. & 1 others, Sullivan, T., Jan 1 2019, In : Journal of Antimicrobial Chemotherapy. 74, 5, p. 1376-1380 5 p.

Research output: Contribution to journal › Article

Lamivudine
HIV-1
RNA
Safety
dolutegravir
4 Citations (Scopus)

Frailty, neurocognitive impairment, or both in predicting poor health outcomes among adults living with human immunodeficiency virus

Erlandson, K. M., Perez, J., Abdo, M., Robertson, K., Ellis, R. J., Koletar, S. L., Kalayjian, R., Taiwo, B. O., Palella Jr, F. J. & Tassiopoulos, K., Jan 1 2019, In : Clinical Infectious Diseases. 68, 1, p. 131-138 8 p.

Research output: Contribution to journal › Article

HIV
Health
Activities of Daily Living
CD4 Lymphocyte Count
Observational Studies

Initial Antiretroviral Therapy in an Integrase Inhibitor Era: Can We Do Better?

Kelly, S. G., Masters, M. C. & Taiwo, B. O., Sep 1 2019, In : Infectious disease clinics of North America. 33, 3, p. 681-692 12 p.

Research output: Contribution to journal › Review article

Integrase Inhibitors
Drug Therapy
Reverse Transcriptase Inhibitors
Lamivudine
Virus Diseases